StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AGEN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $3.47 | $3.58 | +3.17% | 0.4M |
| 05-15 | $3.52 | $3.58 | +1.70% | 0.5M |
| 05-18 | $3.56 | $3.16 | -11.24% | 1.0M |
| 05-19 | $3.20 | $3.09 | -3.44% | 0.7M |
| 05-20 | $3.12 | $3.15 | +0.96% | 0.5M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $33.74M | $114.20M | $79.99M | $49.76M |
Operating Income | $15.05M | $-20.17M | $-34.57M | $-30.02M |
Net Income | $39.21M | $-3.08M | $7.53M | $-30.01M |
EPS (Diluted) | $1.02 | $0.00 | $0.37 | $-2.03 |
Total Assets | $186.46M | $226.80M | $233.89M | $185.22M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $35.00M | $3.00M | $3.46M | $9.53M |
Free Cash Flow OCF − CapEx | $-35.95M | $-77.20M | $-60.58M | $-45.85M |
Shares Outstanding | 38.52M | 35.32M | 32.81M | 30.00M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.